The panelists will discuss the latest innovation in the field of genomic medicine - the gains to be made by rapid iteration and advanced analytics and the ethical considerations and tradeoffs that underlie these innovative approaches

Panelists

DANNIELLE APPELHANS

CTO and SVP Technical Ops, Novartis Gene Therapies

Dannielle Appelhans leads manufacturing, technical development, supply chain, engineering and operations strategy for all clinical and commercial assets at Novartis Gene Therapies. 

Since joining Novartis in 2014, Dannielle has held roles within Novartis and Sandoz Biopharmaceuticals, serving most recently as Novartis’ Global Head of Supply Chain, where she was responsible for the global end-to-end supply chain for all Novartis divisions. Prior to joining Novartis, she held leadership positions in pharmaceutical manufacturing at Eli Lilly & Company and consulting at McKinsey & Company.

Dannielle holds a Bachelor of Science in Mechanical Engineering from the University of Michigan, as well as a Master of Business Administration and a Master of Mechanical Engineering from the Massachusetts Institute of Technology.

SANDY MACRAE

CEO, Sangamo Therapeutics

Sandy Macrae, M.B., Ch.B., Ph.D., has served as Sangamo’s President and Chief Executive Officer and as a member of the Board of Directors since June 2016. He has twenty years of experience in the pharmaceutical industry, most recently serving as the Global Medical Officer of Takeda Pharmaceuticals from 2012 to March 2016, where he established and led the Global Medical Office. From 2001 to 2012, Dr. Macrae held roles of increasing responsibility at GlaxoSmithKline, including Senior Vice President, Emerging Markets Research and Development (R&D), from 2009 to 2012. In that position, he provided expertise and resources to create a first-of-its-kind group to expand GSK’s global reach. From 2007 to 2008, he was Vice President, Business Development, and was responsible for scientific assessment and business development project leadership for the neurology, psychiatry, cardiovascular and metabolic therapeutic areas. Earlier in his career, he worked for SmithKline Beecham, where he was responsible for clinical development in neurology and gastroenterology.

Dr. Macrae received his B.S. in pharmacology and his M.B., Ch.B. with honors from Glasgow University. He is a member of the Royal College of Physicians. Dr. Macrae also earned his Ph.D. in molecular genomics at King’s College, Cambridge.

JODI COOK

CEO and Co-founder, Stratify Therapeutics

Jodi A. Cook, Ph.D.  is CEO and co-founder of Stratify Therapeutics, a company focused on developing a portfolio of innovative therapeutics for rare diseases.  Previously, she was Head of Gene Therapy Strategy for PTC Therapeutics, Inc. since August 2018.  In that role, Dr. Cook led cross-functional gene therapy programs from research through commercialization for treatments of rare diseases with high unmet medical needs. She was a founding member and Chief Operating Officer of Agilis Biotherapeutics from 2013 until its acquisition in 2018. Dr. Cook has more than 20 years of senior executive experience in the life-sciences industry and held leadership positions in several successful biotech start-up companies. She was previously Assistant Professor of Audiology at Mayo Medical School and Director of the Hearing Aid Program at Mayo Clinic in Rochester, MN. 

Dr. Cook began her career as Assistant Clinical Professor conducting research and teaching at Arizona State University.  She earned a BA from Loyola College in Maryland, an M.Aud. from the University of South Carolina, and her Ph.D. in Auditory Science at Arizona State University and completed a fellowship at Johns Hopkins School of Medicine. 

Moderator